Guidelines of the Brazilian Society of Cardiology - Percutaneous coronary intervention and joint diagnostic methods in interventional cardiology (II Edition - 2008);Diretrizes da Sociedade Brasileira de Cardiologia - Intervençã o coronária percutânea e métodos adjuntos diagnósticos em cardiologia intervencionista (II Edição - 2008)

Arquivos Brasileiros de Cardiologia

Volumn 91, Issue 6 SUPPLEMENT, 2008, Pages 1-58

  Mattos, Luiz Alberto ^a   Lemos Neto, Pedro Alves ^a   Rassi Jr , Anis ^a   Marin Neto, José Antonio ^a   Sousa, Amanda Guerra De Moraes Rego ^a   Devito, Fernando Stucchi ^a   Ribeiro Da Silva, Expedito E ^a   De Brito Jr , Fábio Sândoli ^a   De Andrade, Jadelson Pinheiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

'TAXUS'; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; DOBUTAMINE; DOPAMINE; ENOXAPARIN; EPTIFIBATIDE; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; NADROPARIN; NORADRENALIN; PACLITAXEL; PROBUCOL; RAPAMYCIN; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOTAROLIMUS;

ANGINA PECTORIS; ANGIOGRAPHY; ARTERY RECONSTRUCTION; BLEEDING; BLOOD VESSEL DIAMETER; BRACHIAL ARTERY; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CATHETER ABLATION; CHRONIC DISEASE; CLINICAL TRIAL; COMPRESSION BANDAGE; CONSERVATIVE TREATMENT; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY PERFORATION; CORONARY ARTERY PRESSURE; CORONARY STENT; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EVIDENCE BASED PRACTICE; FEMORAL ARTERY; FIBRINOLYSIS; FRACTIONAL FLOW RESERVE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEMOSTASIS; HUMAN; HYPOLIPEMIA; HYPOTENSION; INTERVENTION STUDY; INVASIVE PROCEDURE; MORPHOLOGY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RADIAL ARTERY; RECOMMENDED DRUG DOSE; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SILENT MYOCARDIAL ISCHEMIA; ST SEGMENT; STABLE ANGINA PECTORIS; THROMBOSIS; TREATMENT INDICATION; VASCULAR ACCESS; VEIN GRAFT;

EID: 60449112843     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (243)

1. Cardoso CO, Quadros AS, Mattos LA, Gottschall CA, SarmentoLeite RE, Marin-Neto JA. Perfil de uso dos stents farmacológicos no Brasil: dados da Central Nacional de Intervenções Cardiovasculares (CENIC). Arq Bras Cardiol. 2007;89:356-61.
2. Sousa AGMR, Mattos LA, Campos Neto CM, Carvalho HG, Stella FP, Nunes G. Intervenções percutâneas para revascularização do miocárdio no Brasil em 1996 e 1997 comparadas às do biênio 1992-1993. Relatório do Registro CENIC (Central Nacional de Intervenções Cardiovasculares). Arq Bras Cardiol. 1998;70:423-30.
3. Guimarães JI, Sousa JE, Ribeiro E, Mattos LA, Sousa AGMR, Nunes G, et al. Diretriz de indicações e utilizações das intervenções percutâneas e stent intracoronariano na prática clínica. Arq Bras Cardiol. 2003;80(Suppl 1):1-14.
4. Harrel L, Schunkert H, Palacios IF. Risk predictors in patients scheduled for percutaneous coronary revascularization. Catheter Cardiovasc Interv. 1999;48:253-60.
5. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patients selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990;82:1193-202.
6. Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997; 30:1428-36.
7. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37:2215-38.
8. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-286.
9. Krone RJ, Shaw RE, Klein LW, Block PC, Anderson HV, Weintraub WS, et al. ACC-National Cardiovascular Data Registry. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions lesion classification system in the current "stent era" of coronary interventions (from the ACC-National Cardiovascular Data Registry). Am J Cardiol. 2003;92:389-94.
10. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI)trial. Phase-I findings. N Engl J Med. 1985; 312:932-6.
11. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007;116:2634-53.
12. de Feyter PJ, van den Brand M, Laarman GJ, van Domburg R, Serruys PW, Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management and follow-up. Circulation. 1991;83:927-36.
13. Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol. 1991;68:467-71.
14. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. A pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-71.
15. Lang NN, Newby DE. Emerging thrombotic effects of drug eluting stents. Arterioscler Thromb Vasc Biol. 2007;27:261-2.
16. Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007;50:109-18.
17. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872-8.
18. Kuntz RE, Baim DS. Defining coronary restenosis: newer clinical and angiographic paradigms. Circulation. 1993; 88:1310-23.
19. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804-47.
20. Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, van der Wieken R. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol. 1997;29:1269-75.
21. Agostoni P, Biondi-Zoccai GGL, de Benedict's ML, Rigattieri S, Turzi M, Anselmi M, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures. Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44:349-56.
22. Koreny M, Riedmüller E, Nikfardjam M, Siostrzonek P, Müllner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA. 2004;291:350-7.
23. Katritsis DG, Ioannidis J. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005; 111:2906-12.
24. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16.
25. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283-91.
26. Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O'Neill WW, et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol. 2007; 16:1598-603.
27. Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007;116:2762-72.
28. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, et al. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-660.
29. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
30. Nicolau JC, Timerman A, Piegas LS, Marin-Neto JA, Rassi A. Jr. Guidelines for unstable angina and non-ST-segment elevation myocardial infarction of the brazilian society of cardiology (II Edition, 2007). Arq Bras Cardiol. 2007; 89(4):e89-e131.
31. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48:1319-25.
32. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003;290:1593-9.
33. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al. Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095-104.
34. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
35. PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow-up and analysis of individual patient data from randomized trials. Am Heart J. 2003;145:47-57.
36. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/ AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117:296-329.
37. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, Kastrati A, et al. Coronary stenting versus balloon angioplastyfor acute myocardial infarction: A meta-regression analysis of randomized trials. Int J Cardiol. 2008;126:37-44.
38. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261-95.
39. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, et al. Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT). Thrombolytic therapy versus primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287:1943-51.
40. Dehmer GJ, Kutcher MA, Dey SK, Shaw RE, Weintraub WS, Mitchell K, et al. Frequency of percutaneous coronary interventions at facilities without on-site cardiac surgical backup: a report from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). Am J Cardiol. 2007;99:329-32.
41. American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures), King SB 3rd, Aversano T, Ballard WL, Beekman RH 3rd, Cowley MJ, Ellis SG, et al. ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures). Circulation. 2007;116:98-124.
42. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809-14.
43. Faxon DP. Development of systems of care for ST-elevation myocardial infarction patients: current state of ST-elevation myocardial infarction care. Circulation. 2007;116(2):e29-32.
44. Jacobs AK, Antman EM, Faxon DP, Gregory T, Solis P. Development of systems of care for ST-elevation myocardial infarction patients: executive summary. Circulation. 2007;115:398-401.
45. Aguirre FV, Varghese JJ, Kelley MP, Lam W, Lucore CL, Gill JB, et al. Stat Heart Investigators. Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. Circulation. 2008;117:1145-52.
46. Thune JJ, Hoefsten DE, Lindholm MG, Mortensen LS, Andersen HR, Nielsen TT, et al. Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI)-2 Investigators. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation. 2005;112:2017-21.
47. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation. 2007;116:721-8.
48. Le May MR, So DY, Dionne R, Glover CA, Froeschl MP, Wells GA, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2008;358:231-40.
49. Jollis JG, Roettig ML, Aluko AO, Anstrom KJ, Applegate RJ, Babb JD, et al. Reperfusion of Acute Myocardial Infarction in North Carolina Emergency Departments (RACE) Investigators. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA. 2007;298:2371-80.
50. Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006;48:1326-35.
51. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, Foody JM, Krumholz HM, Phillips CO, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:422-30.
52. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367:579-88.
53. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205-17.
54. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371:559-68.
55. Dzavík V, Buller CE, Lamas GA, Rankin JM, Mancini GB, Cantor WJ, et al. TOSCA-2 Investigators. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation. 2006; 114:2449-57.
56. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395-407.
57. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008; 117:686-97.
58. Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K, et al. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK Investigators. Outcome of patients aged > or =75 years in the Should we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J. 2005;149:1128-34.
59. Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation. 2005;111:940-53.
60. Narayan KMV, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of Recent Increase in Incidence on Future Diabetes Burden. Diabetes Care. 2006;29:2114-6.
61. Herlitz J, Karlson BW, Lindqvist J, Sjolin M. Rate and mode of death during 5 years of follow-up among patients with acute chest pain with and without a history of diabetes mellitus. Diabet Med. 1998;15:308-14.
62. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. Circulation. 2004;109:476-80.
63. DeVriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-74.
64. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis, epidemiology, pathophysiology and management. JAMA. 2002;287:2570-81.
65. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Inamura M, et al. High glucose levels and free fatty acids stimulate reactive oxygen species production through protein kinase C dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-45.
66. Vinik AI, Erbas T, Park TS. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;7:132-7.
67. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2004; 116(Suppl 5A):11S-22S.
68. Boyden TF, Nallamothu BK, Moscucci M, Chan PS, Grossman PM, Tsai TT, et al. Meta-Analysis of Randomized Trials of Drug-Eluting Stents Versus Bare Metal Stents in Patients With Diabetes Mellitus. Am J Cardiol. 2007;99:1399-402.
69. Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR Jr. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007; 49:1611-8.
70. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation. 2005;112:2364-72.
71. Stone GW, Reifart NJ, Moussa I, Hoye A, Cox DA, Colombo A, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation. 2005;112:2530-7.
72. Agostoni P, Valgimigli M, Biondi-Zoccai GGL, Abbate A, Garcia HM, Anselmi M, et al. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am Heart J. 2006;151:682-9.
73. Lefevre T. Bifurcation lesions: the simpler, the better. Rev Esp Cardiol. 2005;58:1261-5.
74. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol. 2005; 46:1446-55.
75. Kimura BJ, Russo RJ, Bhargava V, McDaniel MB, Peterson KL, DeMaria AN. Atheroma morphology and distribution in proximal left anterior descending coronary artery: invivo observations. J Am Coll Cardiol. 1996;27:825-31.
76. Richter Y, Groothuis A, Seifert P, Edelman ER. Dynamic flow alterations dictate leukocyte adhesion and response to endovascular interventions. J Clin Invest. 2004;113:1607-14.
77. Lefevre T, Louvard Y, Morice MC, Dumas P, Loubeyre C, Benslimane A, et al. Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv. 2000;49:274-83.
78. Al Suwaidi J, Yeh W, Cohen HA, Detre KM, Williams DO, Holmes DR Jr. Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol. 2001;87:1139-44.
79. Hoye A, Iakovou I, Ge L, van Mieghem CA, Ong AT, Cosgrave J, et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol. 2006;47:1949-58.
80. Kelbaek H, Kløvgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrøm T, et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J Am Coll Cardiol. 2008;51:2011-6.
81. Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation. 1990;82:1629-46.
82. Lima RC, Kubrusly LF, Nery AC, Pinheiro BB, Brick AV, de Souza DS, et al. Guidelines for myocardial revascularization surgery. Arq Bras Cardiol. 2004;82(Suppl 5):1-20.
83. Ribeiro AL, Gagliardi SP, Nogueira JL, Silveira LM, Colosimo EA, Lopes do Nascimento CA. Mortality related to cardiac surgery in Brazil, 2000-2003. J Thorac Cardiovasc Surg. 2006;131(4):907-9.
84. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med. 2007;147:703-16.
85. Pocock SJ, Henderson RA, Rickards AF, Hampton JR, King SB 3rd, Hamm CW, et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet. 1995;346:1184-9.
86. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the arterial revascularization therapies study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575-81.
87. Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg. 2005;130:512-9.
88. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352:2174-83.
89. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents versus coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008;358:331-41.
90. Hannan EL, Racz M, Holmes DR, Walford G, Sharma S, Katz S, et al. Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. Circulation. 2008;117:2071-8.
91. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, et al. Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary arterydisease. Circulation. 2008;117:2079-86.
92. Seung KB, Park DW, Kim YH, Lee SW, Lee CW, Hong MK, et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med. 2008;358:1781-92.
93. Taggart DP, Kaul S, Boden WE, Ferguson TB Jr, Guyton RA, Mack MJ, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol. 2008;51:885-92.
94. Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008;51:538-45.
95. Guimarães JI, Abizaid A, Costantine C, Mattos LA, Caixeta A, Stadler N, et al. Guidelines for the indications of intracoronary ultrasonography in clinical practice. Arq Bras Cardiol. 2003;81(Suppl 2):1-10.
96. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37:1478-92.
97. Abizaid AS, Mintz GS, Abizaid A, Mehran R, Lansky AJ, Pichard AD, et al. One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms. J Am Coll Cardiol. 1999;34:707-15.
98. Abizaid AS, Mintz GS, Mehran R, Abizaid A, Lansky AJ, Pichard AD, et al. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. Circulation. 1999;100:256-61.
99. Casella G, Klauss V, Ottani F, Siebert U, Sangiorgio P, Bracchetti D. Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: a meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. Catheter Cardiovasc Interv. 2003;59:314-2.
100. Pijls NH, Van Gelder B, Van Der Voort P, Peels K, Bracke FA, Bonnier HJ, et al. Fractional flow reserve: a useful index to evaluate the influence of an epicardial coronary stenosis ion myocardial blood flow. Circulation. 1995; 92:3183-93.
101. Pijls NH, De Bruyne B, Bech GJ, Liistro F, Heyndrickx GR, Bonnier HJ, et al. Coronary pressure measurement to assess the hemodynamic significance of serial stenoses within one coronary artery. Circulation. 2000;102:2371-7.
102. Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis - A Randomized Trial. Circulation. 2001;103:2928-34.
103. Moses JW, Carlier S, Moussa I. Lesion preparation prior to stenting. Rev Cardiovasc Med. 2004;5(Suppl 2):S16-21.
104. Dill T, Dietz U, Hamm C, Kuchler R, Rupprcht H, Haud M, et al. A randomized comparison of balloon angioplasty versus rotational atherectomy in complex coronary lesion (COBRA study) Pilot. Eur Heart J. 2000;21:1759-66.
105. Whitlow P, Bass T, Kipperman R, Sharf B, Ho K, Cutlip D, et al. Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). Am J Cardiol. 2001;87:699-705.
106. Safian R, Feldman T, Muller D, Mason D, Schreiber T, Haik B, et al. Coronary angioplasty and rotablator atherectomy trial (CARAT): immediate and late results of a prospective multicentre randomized trial. Catheter Cardiovasc Interv. 2001;53:213-20.
107. vom Dahl J, Dietz U, Haager P, Silber S, Niccoli L, Buettner II, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse instent restenosis trial (ARTIST). Circulation. 2002;105:583-8.
108. Sharma S, Kini A, Mehran R, Lansky A, Kobyashi Y, Marmur J. Randomized trial of rotational atherectomy versus balloon angioplasty of diffuse in-stent restenosis (ROSTER). Am HeartJ. 2004;147:16-22.
109. Adamian M, Colombo A, Briguori C, Nishida T, Marsico F, Di Mario C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol. 2001;38:672-9.
110. Mauri L, Bonan R, Weiner BH, Legrand V, Bassand JP, Popma JJ, et al. Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002;90:1079-83.
111. Kurbaan AS, Kelly PA, Sigwart U. Cutting balloon angioplasty and stenting for aorto-ostial lesions. Heart. 1997;77:350-2.
112. Kurbaan AS, Foale RA, Sigwart U. Cutting balloon angioplasty for in-stent restenosis. Cathet Cardiovasc Interv. 2000;50:480-3.
113. Albiero R, Nishida T, Karvouni E, Corvaja N, Vaghetti M, Di Mario C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis. Cathet Cardiovasc Interv. 2000;50:452-9.
114. Ahmed JM, Mintz GS, Weissman NJ, Lansky AJ, Pichard AD, Satler LF, et al. Mechanism of lumen enlargement during intracoronary stent implantation: an intravascular ultrasound study. Circulation. 2000;102:7-10.
115. Mauri L, Rogers C, Baim DS. Devices for distal protection during percutaneous coronary revascularization. Circulation. 2006;113:2651-6.
116. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Neumann FJ, Chiariello M. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. Am Heart J. 2007;153:343-53.
117. Coolong A, Baim DS, Kuntz RE, O'Malley AJ, Marulkar S, Cutlip DE et al. Saphenous Vein Graft Stenting and Major Cardiac Adverse Events: A Predictive Model Derived from a Pooled Analysis of 3958 patients. Circulation 2008;117:790-97.
118. Kelbaek H, Terkelsen CJ, Helqvist S, Lassen JF, Clemmensen P, Kløvgaard L, et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol. 2008;51:899-905.
119. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557-67.
120. Stone GW, Ohman EM, Miller MF, Joseph DL, Christenson JT, Cohen M, et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol. 2003;41:1940-5.
121. Briguori C, Sarais C, Pagnotta P, Airoldi F, Liistro F, Sgura F, et al. Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty. Am Heart J. 2003;145:700-7.
122. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-88.
123. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-9.
124. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-71.
125. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients wfm coronary artery disease (Benestent II). Lancet 1998;352:673-81.
126. Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PP, Henry T, et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet. 2000;355:2199-203.
127. Mattos LA, Pinto I, Abizaid A, Abizaid A, Chaves A, Feres F, et al. Safety and efficacy of coronary stent implantation. Acute and six month outcomes of 1,126 consecutive patients treated in 1996 and 1997. Arq Bras Cardiol. 1999;73:23-36.
128. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-9.
129. Kastrati A, Schömig A, Dirschinger J, Mehilli J, von Welser N, Pache J, et al. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation. 2000; 101:2478-83.
130. Pache J, Kastrati A, Mehilli J, Schühlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283-8.
131. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002;40:403-9.
132. Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol. 2002;40:1021-33.
133. Dawkins KD, Chevalier B, Suttorp MJ, Thuesen L, Benit E, Bethencourt A, et al. Effectiveness of "direct" stenting without balloon predilatation (from the Multilink Tetra Randomised European Direct Stent Study [TRENDS]). Am J Cardiol. 2006;97:316-21.
134. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247-54.
135. Mercado N, Boersma E, Wijns W, Cersh BJ, Morillo CA, de Valk V, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol. 2001;38:645-52.
136. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Periprocedural quantitative coronary angiography after PalmazSchatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the Belgian Netherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol. 1999;34:1067-74.
137. Serruys PW. Fourth annual American College of Cardiology international lecture: a journey in the interventional field. J Am Coll Cardiol. 2006;47:1754-68.
138. Kuchulakanti P, Waksman R. Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. Drugs. 2004;64:2379-88.
139. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109:1948-54.
140. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867-73.
141. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation. 2002;106:2734-40.
142. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation. 2002;106:2859-66.
143. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-5.
144. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimuseluting stents. Circulation. 2005;111:2326-9.
145. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003;107:2274-9.
146. Sousa JE, Costa MA, Tuzcu EM, Yadav JS, Ellis S. New frontiers in interventional cardiology. Circulation. 2005; 111:671-81.
147. Daemen J, Serruys PW. Drug-eluting stent update 2007: part I. A survey of current and future generation drugeluting stents: meaningful advances or more of the same? Circulation. 2007;116:316-28.
148. Daemen J, Serruys PW. Drug-eluting stent update 2007: part II. A survey of current and future generation drugeluting stents: meaningful advances or more of the same? Circulation. 2007;116:961-8.
149. Baim DS, Mehran R, Kereiakes DJ, Gross TP, Simons M, Malenka D, et al. Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach. Circulation. 2006;113:891-7.
150. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation. 2007;115:2352-7.
151. Maisel WH, Laskey WK. Cardiology patient page. Drugelutingstents. Circulation. 2007;115:e426-7.
152. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583-91.
153. Stealer C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and baremetal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48.
154. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation. 2005;111:3435-42.
155. Pinto Slottow TL, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent. Circulation. 2008;117:1603-8.
156. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-13.
157. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholineencapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
158. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48:2440-7.
159. Serruys PW, Ong ATL, Piek J, Neumann FJ, van der Giessen WJ, Wierner M, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2005;1:58-65.
160. Serruys PW, Ruygrok P, Neuzner J, Piek J, Seth A, Schofer J, et al. A randomized comparison of an everolimuseluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286-94.
161. Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices. 2006; 3:731-41.
162. Costa RA, Lansky AJ, Abizaid A, Müeller R, Tsuchiya Y, Mori K, et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol. 2006;98:443-6.
163. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004;43:8-14.
164. De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, et al. Efficacy and safety of drugeluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Int J Cardiol. 2008 Apr 2. [Epub ahead of print].
165. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-9.
166. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
167. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292:2727-34.
168. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215-23.
169. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306-13.
170. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, et al. Vessel size and outcome after coronary drugeluting stent placement: results from a large cohort of patients treated with sirolimus or paclitaxel-eluting stents. J Am Coll Cardiol. 2006;48:1304-9.
171. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimuseluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-5.
172. Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation. 2006;114:2148-53.
173. Petronio AS, De Carlo M, Branchitta G, Papini B, Ciabatti N, Gistri R, et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol. 2007;49:539-46.
174. Iakovou I, Ge L, Michev I, Sangiorgi GM, Montorfano M, Airoldi F, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol. 2004;44:967-71.
175. Seung KB, Kim YH, Park DW, Lee BK, Lee CW, Hong MK, et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol. 2005;46:787-92.
176. Vijayakumar M, Rodriguez Granillo GA, Lemos PA, Aoki J, Hoye A, Ong AT, et al. Sirolimus-eluting stents for the treatment of atherosclerotic ostial lesions. J Invasive Cardiol. 2005;17:10-2.
177. Tsagalou E, Stankovic G, Iakovou I, Melzi G, Cosgrave J, Ge L, et al. Early outcome of treatment of ostial de novo left anterior descending coronary artery lesions with drug- eluting stents. Am J Cardiol. 2006;97:187-91.
178. Park DW, Hong MK, Suh IW, Hwang ES, Lee SW, Jeong YH, et al. Results and predictors of angiographic restenosis and long-term adverse cardiac events after drug-eluting stent implantation for aorto-ostial coronary artery disease. Am J Cardiol. 2007;99:760-5.
179. de Feyter PJ. Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem. Circulation. 2003;107:2284-6.
180. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol. 2004;16:230-3.
181. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45:989-94.
182. Price MJ, Sawhney N, Kao JA, Madrid A, Schatz RA, Teirstein PS. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv. 2005;65:208-11.
183. Tsuchida K, Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M, et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol. 2005;96:395-8.
184. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol. 2006;97:34-7.
185. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six month angiographic, intravascular ultrasound, and clinical follow-upof the RRISC Trial. J Am Coll Cardiol. 2006;48:2423-31.
186. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-7.
187. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-34.
188. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimuseluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006;114:921-8.
189. Cosgrave J, Melzi G, Biondi-Zoccai GG, Airoldi F, Chieffo A, Sangiorgi GM, et al. Drug-eluting stent restenosis: the pattern predicts the outcome. J Am Coll Cardiol. 2006;47:2399-404.
190. Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Minguez JR, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003;42:796-805.
191. Alfonso F, Augé JM, Zueco J, Bethencourt A, López Mínguez JR, Hernández JM, et al. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol. 2005;46:756-60.
192. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of instent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2003;107:24-7.
193. Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:616-23.
194. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation. 2004;109:2500-2.
195. Weisz C, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006;47:1350-5.
196. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006;113:2293-300.
197. Sianos G, Hofma S, Ligthart JM, Saia F, Hoye A, Lemos PA, et al. Stent fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv. 2004;61:111-6.
198. Garg S, Smith K, Torguson R, Okabe T, Slottow TL, Waksman R. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent Catheter Cardiovasc Interv. 2007;70:9-14.
199. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Babic R, Airoldi F, et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J. 2007;153:354-9.
200. Kim YH, Lee BK, Park DW, Park KH, Choi BR, Lee CW, et al. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis. Am J Cardiol. 2006;98:1451-4.
201. Biondi-Zoccai GG, Lotrionte M, Moretti C, Meliga E, Agostoni P, Valgimigli M, et al. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. Am Heart J. 2008;155:274-83.
202. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, et al. A Comparison of BareMetal and Drug-Eluting Stents for Off-Label Indications. N Eng J Med. 2008;358:342-52.
203. Briguori C, Nishida T, Anzuini A, Di Mario C, Grube E, Colombo A. Emergency polytetrafluoethylene covered stent implantation to treat coronary ruptures. Circulation. 2000; 102:3028-31.
204. Doyle B, Rihal CS, O'Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with baremetal coronary stents. Circulation. 2007;116:2391-8.
205. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol. 2007;49:1043-51.
206. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-elutingstents. JAMA. 2005;293:2126-30.
207. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005;95:509-10.
208. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20.
209. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2007;100:1199-206.
210. Bavry AA, Lincoff AM. Is clopidogrel cardiovascular medicine's double-edged sword? Circulation. 2006;113:1638-40.
211. von Tiehl KF, Price MJ, Valencia R, Ludington KJ, Teirstein PS, Simon RA. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol. 2007;50:2039-43.
212. Popma JJ, Weitz J, Bittl JA, Ohman EM, Kuntz RE, Lansky AJ, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 1998;114:728S-41S.
213. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978;26:231-40.
214. Brack MJ, More RS, Hubner PJ, Gershlick AH. The effect of low dose nitroglycerin on plasma heparin concentration and activated partial thromboplastin times. Blood Coagul Fibrinolysis. 1993;4:183-6.
215. O'Neill WW. Risk of bleeding after elective percutaneous coronary intervention. N Engl J Med. 2006;355:1058-60.
216. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54.
217. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042-50.
218. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355:1006-17.
219. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477-88.
220. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-98.
221. Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol. 2007;23:963-70.
222. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F, et al. Influence of treatment duration with a 600-mg dose of Clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. 2004;44:2133-6.
223. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT2 randomized trial. JAMA. 2006;295:1531-8.
224. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759-65.
225. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
226. Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, et al. IV Brazilian Guideline for Dyslipidemia and Atherosclerosis Prevention: Department of Atherosclerosis of Brazilian Society of Cardiology. Arq Bras Cardiol. 2007;88(Suppl 1):2-19.
227. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750-6.
228. Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, et al. Systematic review and meta analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J. 2008;155:1081-9.
229. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol. 2006; 47:1522-9.
230. Brito FS Jr, Rosa WC, Arruda JA, Tedesco H, Pestana JO, Lima VC. Efficacy and safety of oral sirolimus to inhibitin-stent intimal hyperplasia. Catheter Cardiovasc Interv. 2005;64:413-8.
231. Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Feres F, Staico R, et al. Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study. Catheter Cardiovasc Interv. 2005;66:535-40.
232. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H, et al. Randomized, double-blind, pla- cebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004;110:790-5.
233. Schweiger MJ, Chambers CE, Davidson CJ, Blankenship J, Bhalla NP, Block PC, et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv. 2007;69:135-40.
234. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113:1799-806.
235. Tepel M. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:1853-5.
236. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A metaanalysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692-9.
237. Dixon SR, Grines CL, O'Neill WW. The year in interventional cardiology. J Am Coll Cardiol. 2007;50:270-85.
238. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48:924-30.
239. Reed PS, Dixon SR, Boura JA, O'Neill WW, Kahn JK. Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. Am J Cardiol. 2007;100:1090-3.
240. van den Brand MJ, Rensing BJ, Morel MA, Foley DP, de Valk V, Breeman A, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol. 2002;39:559-64.
241. Ruygrok PN, Melkert R, Morel MA, Ormiston JA, Bär FW, Fernandez-Avilès F, et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol. 1999;34:1507-11.
242. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol. 2007;50:1707-32.
243. Brotman DJ, Bakhru M, Saber W, Aneja A, Bhatt DL, Tillan-Martinez K, et al. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. J Hosp Med. 2007;2:378-84.